Sensei Biotherapeutics IncNASDAQ:SNSE
- LAST PRICE1.5000
- TODAY'S CHANGE (%)0.0050 (0.3344%)
- Bid / Lots1.4400/ 5
- Ask / Lots1.6100/ 10
- Open / Previous Close1.5100 / 1.4950
- Day Range
- 52 Week Range
- Volume36,015
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SNSE |
|---|---|---|
| 09:32 ET | 477 | 1.51 |
| 09:35 ET | 723 | 1.55 |
| 09:46 ET | 300 | 1.51 |
| 09:51 ET | 1100 | 1.54 |
| 09:53 ET | 1628 | 1.5442 |
| 10:09 ET | 2920 | 1.5201 |
| 10:11 ET | 300 | 1.51 |
| 10:13 ET | 415 | 1.51 |
| 10:27 ET | 300 | 1.51 |
| 10:33 ET | 1200 | 1.5102 |
| 10:36 ET | 751 | 1.51 |
| 10:42 ET | 2026 | 1.52 |
| 10:54 ET | 200 | 1.51 |
| 11:05 ET | 200 | 1.51 |
| 11:07 ET | 1000 | 1.515 |
| 11:18 ET | 100 | 1.51 |
| 11:21 ET | 300 | 1.51 |
| 11:23 ET | 3209 | 1.51 |
| 11:25 ET | 250 | 1.5095 |
| 11:30 ET | 100 | 1.5 |
| 11:34 ET | 300 | 1.5 |
| 11:39 ET | 715 | 1.5 |
| 11:43 ET | 100 | 1.5 |
| 11:45 ET | 200 | 1.5 |
| 11:48 ET | 100 | 1.5 |
| 11:52 ET | 100 | 1.5 |
| 11:56 ET | 100 | 1.5 |
| 11:59 ET | 190 | 1.5 |
| 12:01 ET | 100 | 1.495 |
| 12:14 ET | 100 | 1.49 |
| 12:19 ET | 100 | 1.49 |
| 12:21 ET | 500 | 1.5 |
| 12:26 ET | 100 | 1.495 |
| 12:37 ET | 200 | 1.49 |
| 12:42 ET | 100 | 1.495 |
| 12:55 ET | 100 | 1.49 |
| 01:00 ET | 1700 | 1.5 |
| 01:06 ET | 1100 | 1.515 |
| 01:18 ET | 100 | 1.51 |
| 01:20 ET | 100 | 1.515 |
| 01:26 ET | 100 | 1.51 |
| 01:29 ET | 100 | 1.51 |
| 01:31 ET | 100 | 1.51 |
| 01:33 ET | 100 | 1.51 |
| 01:36 ET | 100 | 1.51 |
| 01:38 ET | 800 | 1.5101 |
| 01:40 ET | 100 | 1.51 |
| 01:42 ET | 300 | 1.515 |
| 01:44 ET | 100 | 1.51 |
| 01:45 ET | 100 | 1.51 |
| 01:49 ET | 100 | 1.51 |
| 01:54 ET | 100 | 1.51 |
| 01:56 ET | 300 | 1.51 |
| 02:00 ET | 100 | 1.51 |
| 02:02 ET | 100 | 1.515 |
| 02:03 ET | 100 | 1.51 |
| 02:07 ET | 100 | 1.51 |
| 02:09 ET | 100 | 1.51 |
| 02:14 ET | 100 | 1.51 |
| 02:16 ET | 100 | 1.515 |
| 02:18 ET | 100 | 1.51 |
| 02:20 ET | 100 | 1.51 |
| 02:23 ET | 100 | 1.51 |
| 02:27 ET | 100 | 1.51 |
| 02:30 ET | 200 | 1.51 |
| 02:32 ET | 100 | 1.515 |
| 02:34 ET | 100 | 1.51 |
| 02:36 ET | 2900 | 1.52 |
| 02:39 ET | 100 | 1.53 |
| 02:50 ET | 100 | 1.535 |
| 03:01 ET | 100 | 1.53 |
| 03:06 ET | 100 | 1.53 |
| 03:08 ET | 100 | 1.53 |
| 03:12 ET | 100 | 1.53 |
| 03:15 ET | 700 | 1.51 |
| 03:17 ET | 100 | 1.5 |
| 03:26 ET | 100 | 1.5 |
| 03:33 ET | 100 | 1.54 |
| 03:37 ET | 100 | 1.51 |
| 03:39 ET | 100 | 1.51 |
| 03:42 ET | 300 | 1.5 |
| 03:53 ET | 500 | 1.5 |
Yesterday
BRIEF-Sensei Biotherapeutics Signs Research And Development Agreement With National Cancer Institute , from 10:38AM ET on Monday Feb 06, 2023 by Thomson Reuters
10:38AM ET on Monday Feb 06, 2023 by Thomson ReutersSensei Biotherapeutics, National Cancer Institute to Collaborate on SNS-101 Development; Shares Gain Premarket, from 8:42AM ET on Monday Feb 06, 2023 by MT Newswires
8:42AM ET on Monday Feb 06, 2023 by MT NewswiresSensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody, from 7:30AM ET on Monday Feb 06, 2023 by GlobeNewswire
7:30AM ET on Monday Feb 06, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sensei Biotherapeutics Inc | 45.9M | -1.0x | --- |
NextCure Inc | 46.7M | -0.6x | --- |
NLS Pharmaceutics AG | 45.1M | -1.3x | --- |
Monopar Therapeutics Inc | 47.0M | -4.5x | --- |
Immix Biopharma Inc | 43.5M | -0.8x | --- |
Evaxion Biotech A/S | 42.9M | -1.6x | --- |
Company Information
Sensei Biotherapeutics, Inc. is an immuno-oncology company focused on the discovery and development of therapeutics for cancer. The Company has designed two approaches to develop therapeutics its Tumor Microenvironment Activated biologics (TMAb) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the Company is developing SNS-101, human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment. The Company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. The Company has four investigational products in various stages of early development: SNS-101, SNS-102, SNS-103 and SNS-401.
Contact Information
- Headquarters
- 620 Professional DriveGAITHERSBURG, MD, United States 20879
- Phone
- 240-243-8000
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- William Ringo
- President, Chief Executive Officer, Director
- John Celebi
- Chief Financial Officer
- Erin Colgan
- Independent Director
- Samuel Broder
- Independent Director
- Jessie English
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $45.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.49 |
Book Value | $4.79 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
